GlassScriptPhysician profile
Whitney S Boling
NPI 1629333133
$4,845.73
in general payments reported to CMS, 2019-2025
29 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $203 · 2021: $319 · 2022: $617 · 2023: $744 · 2024: $1,162 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.46 |
| Education | $293.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $835.67 | 2019-2025 | Clareon, Clareon Panoptix Pro |
| Mallinckrodt Hospital Products INC. | $799.23 | 2021-2025 | Acthar |
| Glaukos Corporation | $424.09 | 2022-2025 | Idosetr, Istent Infinite, Istent Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $317.10 | 2019-2025 | |
| Amgen INC. | $240.83 | 2024-2025 | Tepezza |
| Genentech USA, INC. | $225.11 | 2022-2024 | Vabysmo |
| Sight Sciences, INC. | $215.88 | 2024-2025 | Omni Surgical System |
| Dompe US, INC. | $199.76 | 2022-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $184.74 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $154.14 | 2019-2025 | Eylea Hd |
| Sun Pharmaceutical Industries INC. | $144.71 | 2020-2023 | Cequa |
| Ocular Therapeutix, INC. | $139.83 | 2020-2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $121.85 | 2021 | |
| Horizon Therapeutics Plc | $110.98 | 2023 | Tepezza, Uplizna |
| Allergan, INC. | $90.08 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $84.91 | 2019-2023 | |
| Abbvie INC. | $82.54 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.88 | 2019 | |
| Staar Surgical Company | $77.23 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $69.76 | 2024 | Xdemvy |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $53.58 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $52.84 | 2023-2025 | Xiidra, Envista Mx60 Iol |
| Oyster Point Pharma, INC. | $28.72 | 2022-2023 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $23.50 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Harrow Eye, LLC | $21.50 | 2025 | Triesence |
| New World Medical,INC. | $20.65 | 2021-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Ziemer USA | $17.13 | 2019 | |
| Romark Laboratories, Lc | $15.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Boling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.